originally discovered as the putative coreceptor for lymphotropic strains of human immunodeficiency virus (HIV) (14) , Although lung cancer, and particularly primary non-small and CXCL12 is its lone CXC chemokine ligand. Both cell lung cancer (NSCLC), is the leading cause of malignancy-CXCL12 Ϫ/Ϫ and CXCR4 Ϫ/Ϫ mice die in utero, and both exrelated mortality in the United States (1, 2) , the biology of hibit similar defects in cardiogenesis, vascular development, this devastating disease is complex and poorly understood.
hematopoiesis, and neuronal development (14) (15) (16) (17) (18) . NSCLC metastases to regional lymph nodes, liver, adrenal Breast cancer metastases, similar in character to NSCLC glands, contralateral lung, brain, and bone marrow are a key metastases, was originally characterized by Paget (19) , who factor in the virulence of this cancer (3, 4) . Experimental data demonstrated that this cancer has a distinct metastatic pattern have demonstrated that sites of metastasis are determined not preferentially involving the regional lymph nodes, bone maronly by the characteristics of neoplastic cells but also by row, lung, and liver. Mü ller and colleagues (20) have provided the microenvironment of the specific organ (5) . The organ new insights into potential mechanisms related to organprovides growth conditions that are optimized for specific specific metastases of breast cancer cells directly related to cancers. Moreover, the ability of cancer cells to traffic to a CXC chemokine. They found that CXCR4 was the most these organs depends on the organ's special abilities to attract highly expressed chemokine receptor in human breast cancer. through chemotactic factors specific types of cancer cells (6) .
The ligand for CXCR4, CXCL12 mRNA, exhibited peak levels In this context, it appears that NSCLC cells can metastasize of expression in organs that are preferential destinations of breast cancer metastasis. Moreover, in vivo neutralization of CXCR4 resulted in significant inhibition of metastases of breast cancer in an organ-specific manner.
(Received in original form January 16, 2003 ; accepted in final form February 17, 2003) mediates a significant portion of primary tumor angiogenesis
RNA Isolation and Reverse Transcription-Polymerase
and angiogenesis-dependent tumor growth.
Chain Reaction
In an effort to address the role of the CXCL12-CXCR4 tant in orchestrating the metastases of NSCLC.
Western Blotting

METHODS
Western blot analysis was performed with an anti-phospho-ERK-1/ 2 antibody (Cell Signaling Technology, Beverly, MA) as previously Reagents described (23, 24). Equal loading of each lane was determined with anti-ERK-1/2 antibodies. The detection of CXCL12 was made with Polyclonal goat anti-CXCL12 antibodies were produced by immunizapolyclonal anti-CXCL12 (R&D Systems). tion with recombinant CXCL12 (PeproTech, Rocky Hill, NJ) as previously described (23, 24). Five hundred microliters of anti-CXCL12 Immunohistochemistry was sufficient to specifically neutralize 1 g of either human or murine CXCL12 in leukocyte chemotaxis assays. Anti-CXCL12 inhibited Immunohistochemistry of tissue specimens was performed as previously CXCL12-mediated endothelial cell and NSCLC cell chemotaxis. Antidescribed (23-27). Factor VIII-related antigen, control antibodies, and proliferating cell Tumor Cell Chemotaxis nuclear antigen (PCNA) antibodies were purchased from Dako (Carpinteria, CA). The apoptosis detection assay was purchased from Roche Chemotaxis of NSCLC cell lines was induced according to methods Molecular Biochemicals (Indianapolis, IN). C3a levels were measured previously described, with modifications (23-27). by the Complement C3a des Arg Correlate-EIA (Assay Designs, Ann Arbor, MI).
Enzyme-linked Immunosorbent Assay Analysis
The quantity of human or murine CXCL12 present in tissue homogeHuman NSCLC Cell Lines nates was determined by specific enzyme-linked immunosorbent assay The Calu-1 and A549 NSCLC cell lines were cultured as previously (ELISA), using a modification of the double-ligand method as predescribed (24-27).
viously described (29).
Statistical Analysis Normal Human Lung and NSCLC Tumor Tissue
The animal studies involved 10 SCID mice for each treatment group. Tissue specimens were obtained in accordance with University of CaliData were analyzed with StatView 5.0 (SAS Institute, Cary, NC). All fornia Los Angeles (UCLA) internal review board approval and progroup comparisons were evaluated by analysis of variance with post hoc cessed as previously described (24, 27 
RESULTS
Mouse Chimeras
Six-to 8-week-old female CB17-SCID beige mice (UCLA Core Facility) CXCR4, but Not CXCL12, Is Expressed in Specimens were injected either subcutaneously or transthoracically (orthotopic; 10 4 of Human NSCLC Tumors cells/25 l) via the left lung with A549 cells, using a modification as Several studies have now shown that CXCR4 is abundantly previously described (24-27). Tumor-bearing mice were intraperitoneexpressed on cells from a number of epithelial cells, metastatic ally injected with neutralizing anti-CXCL12 or preimmune serum, or cancers including ovarian, pancreatic, neuroblastoma, nonreceived no treatment, as previously described (25-27). Tissue and blood samples were processed as previously described (24-27).
Hodgkin's lymphoma, and multiple myeloma and although these tumors arise from different tissues they all share the ability to undergo chemotaxis in the presence of CXCL12 (30, 31). One article has further suggested that CXCL12-CXCR4 biology is important in dictating organ-specific metastases of breast cancer (20). Initially, we wanted to establish whether CXCR4 was expressed on NSCLC cells in tumors resected from patients. To do this, we performed immunohistochemical studies with antibodies specific for CXCR4 on 20 specimens of stage I and II squamous cell carcinoma antigen (SCCA) and 20 samples of Stage I and II adenocarcinoma. Our results indicate that CXCR4 is expressed on a majority (more than 80%) of the tumor cells in either SCCA or adenocarcinoma NSCLC tumor specimens (Figures 1IB and 1ID) . All of the SCCA or adenocarcinoma NSCLC tumor specimens examined expressed positive staining for CXCR4. There was no evidence for nonspecific staining with RNA was prepared from A549 (lanes 1 and 3) and Calu-1 (lanes 2 and the control antibody ( Figures 1IA and 1IC) . Furthermore, there 4) cell lines, reverse transcribed, and then subjected to polymerase chain was evidence of CXCR4 immunolocalization on host responding reaction (PCR) using primer pairs specific for either CXCR4 (lanes 1 and cells, such as tumor-associated macrophages, fibroblasts, and 2) or the housekeeping gene GAPDH (lanes 3 and 4).
endothelial cells (Figures 1IB and 1ID ). In contrast, we found no difference in protein levels of CXCL12 in NSCLC tumors (SCCA and adenocarcinoma), as compared with normal lung tissue as determined by ELISA analysis ( Figure 1II ). noma) and Calu-1 (squamous cell carcinoma) expressed this chemokine receptor. Thus, mRNA was extracted from these
CXCR4 Is Expressed on Human NSCLC Cell Lines
cells, reversed transcribed into cDNA, and analyzed for expression of CXCR4 by PCR. We observed that both cell lines constiHaving established that CXCR4 is present on NSCLC cells in human tumors isolated from patients ( Figure 1I ), we next detertutively expressed mRNA for CXCR4, but not for its cognate ligand, CXCL12 ( Figure 2 , and data not shown). Next, we premined whether the human NSCLC cell lines A549 (adenocarci- for changes in the intracellular calcium concentration in response to either CXCL12␣ (1 ng/ml) or CXCL12␤ (1 ng/ml). Transient calcium flux was observed in A549 and Calu-1 cells stimulated with either isoform of CXCL12 (data not shown), thus confirming results observed in other seven-transmembrane receptor systems including human lymphocytes, megakaryoblasts, and epithelial cells (32, 33).
Subsequently, we assessed whether the expression of CXCR4 was functional in promoting NSCLC cell migration. We performed chemotaxis assays with A549 and Calu-1 cells in the presence or absence of CXCL12␣ (0.001 to 100 ng/ml) and CXCL12␤ (0.001 to 100 ng/ml) ( Figure 5 ). We observed that both CXCL12␣ and CXCL12␤ appeared similarly efficacious in inducing dose-dependent chemotaxis of A549 cells ( Figure 5 ) and Calu-1 cells (data not shown). Finally, to confirm that signal transduction through CXCR4, a G protein-linked receptor, was responsible for the NSCLC cell chemotactic response to CXCL12␣ and CXCL12␤, we tested the ability of pertussis toxin (PTX) to pathway involving a PTX-sensitive G protein.
In addition to chemotaxis, we also examined whether CXCL12 altered the proliferative and apoptotic character of A549 and Calu-1 cells. CXCL12 was not found to induce signifipared whole cell extracts of these cell lines and examined them cant proliferation over the background control levels ( Table 1) . for expression of CXCR4 protein by Western blot analysis, using antibodies specific for CXCR4. As shown in Figure 3A , both This observation was further confirmed by manually counting A549 and Calu-1 cells constitutively express CXCR4 protein, cells at the same time point. In other experiments, A549 and whereas CXCL12 protein is not observed in these cells (Figure Calu-1 cells were cultured in the presence or absence of various 3B). Finally, A549 and Calu-1 cells were subjected to FACS concentrations of CXCL12 and examined for evidence of apoanalysis to look for cell surface expression of CXCR4. Our results ptosis (Table 1) . Our results indicated that the number of A549 show that CXCR4 is observed on a significant number (45 to and Calu-1 cells undergoing apoptosis by terminal deoxynucleo-50%) of A549 and Calu-1 cells (Figures 4A and 4B ). In addition, tidyltransferase-mediated dUTP-biotin nick end-labeling assay CD49b, which is a human epithelial cell-specific marker, is in the presence of CXCL12 was similar to controls (Table 1) . strongly expressed on all (more than 99%) of these NSCLC cell These results suggest that CXCL12 binding to CXCR4 mediates lines ( Figures 4C and 4D) .
chemotaxis without altering the proliferative or apoptotic indices of the NSCLC tumor cells.
CXCR4 Is Functional on Human NSCLC Cell Lines
To further delineate the signal transduction events that might The above-described results indicated that CXCR4 is expressed be responsible for chemotaxis mediated by the CXCL12-CXCR4 on NSCLC cell lines. We next determined whether the receptor biological axis, we investigated the potential role of the mitogenwas functional. Initially, we loaded A549 and Calu-1 cells with activated protein kinase (MAP kinase) pathway. Previous studies the calcium-sensitive dye Indo-1/AM (2 M), and then looked have already established that CXCL12 binding to CXCR4 in normal human megakaryocytes induces downstream phosphorylation of mitogen-activated protein kinase p42/44 (MAP kinase ERK-1/2) and the serine/threonine kinase AKT (32). Therefore, A549 cells were exposed to CXCL12␤ (10 ng/ml) for the times indicated before being solubilized in lysis buffer containing a panel of protease inhibitors. Next, 40 g of total protein from each sample was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to a polyvinylidene difluoride membrane. Subsequent Western blot analysis using anti-phospho-p42/44 antibodies (New England BioLabs, Beverly, MA) revealed that whereas A549 cells constitutively expressed the phosphorylated form of ERK-1/2 (p42/44), addition of CXCL12 resulted in further induction in p42/44 MAP kinase phosphorylation that peaked 5 minutes after stimulation ( Figure 6A ). Reprobing the membrane with anti-p42/44 antibodies (New England BioLabs) revealed that equivalent levels of via a mechanism that also requires a PTX-sensitive G protein. and are capable of utilizing potential CXCL12 chemokine gradiThus, we analyzed CXCL12 protein in tissue homogenates from ents that exist between the primary tumor and metastases. Inthe primary tumor and a panel of murine organs by ELISA.
deed, previous studies have already shown that A549 cells inOur results indicate that significantly higher levels of CXCL12 jected into the flank of mice do spontaneously metastasize (24, protein were observed in the adrenal glands, lung, liver, and 26-28). Thus, to determine whether NSCLC metastases express bone marrow, which are target organs for NSCLC metastasis, CXCR4, we used the heterotopic and orthotopic tumor models whereas CXCL12 expression is barely detectable in the kidney of human A549 cells in SCID mice and 8 weeks later killed and heart, which favors the idea that these organs are not necesthem to examine their metastatic pattern. Cell suspensions of sarily sites for NSCLC tumor metastasis (Figure 7) . Furthermore, the levels of CXCL12 protein observed in the adrenal glands, the primary tumor, adrenal glands, liver, lung, brain, and bone liver, lung, and bone marrow, but not the kidney and heart, marrow were isolated, stained with antibodies specific for CD49b were significantly higher than both the primary tumor and plasma and CXCR4, and analyzed by FACS (Figure 8 ; n ϭ 6 animals/ 6 organs for each type). The strategy implemented here takes advantage of the fact that all A549 cells express human CD49b (Figure 4 ), thus detection of human CD49b-positive cells in Having established the specificity of the anti-CXCL12 antibody, we next investigated whether the administration of neu-( Figure 8I ). Thus about 35% of the CD49b ϩ A549 cells were CXCR4 Ϫ ( Figure 8I ). In addition, when we examined metastases tralizing anti-CXCL12 antibodies to heterotopic or orthotopic A549 tumor-bearing SCID mice attenuated NSCLC tumor mefrom primary heterotopic and orthotopic tumors isolated from the adrenal glands, liver, brain, bone marrow, and lung (heterotastasis. We injected A549 cells heterotopically or orthotopically into SCID mice, and then treated them with intraperitoneal topic only) of A549-xenoengrafted SCID mice, we observed that more than 99% of the NSCLC tumor cells were CD49b (Figures 8II-8VI) . Moreover, analysis of the heart and kidney revealed few if any metastases. Therefore, it for 8 weeks, starting at the time of xenoengraftment. On sacrifice, cells from the lungs (heterotopic model only), seems likely that, in common with breast cancer cells, CXCR4 plays an important role in NSCLC tumor metastasis.
adrenal glands, liver, bone marrow, and brain of A549 heterotopic and orthotopic tumor-bearing mice were isolated and ex-
Depletion of CXCL12 Inhibits NSCLC Metastases
amined for signs of spontaneous metastases by FACS analysis of CD49b. Depletion of CXCL12 in the heterotopic NSCLC On the basis of the above-described results, we wanted to detertumor model resulted in markedly attenuated metastases to the mine whether the systemic depletion of CXCL12 by specific lung ( Figures 9I and 9II ). Depletion of CXCL12 in both heteroneutralizing antibodies to CXCL12 in SCID mice bearing A549 topic and orthotopic NSCLC tumor models significantly imheterotopic and orthotopic tumors would attenuate NSCLC tupaired metastases to the adrenal glands, bone marrow, liver, and mor metastasis. We used anti-CXCL12 rather than anti-CXCR4 brain ( Figure 10 ). In control SCID mice that lacked human tumors, antibodies to eliminate the possibility that anti-CXCR4 antibodCD49b-positive cells were not detected. These data support the ies could promote clearance of CXCR4-expressing A549 cells from the circulation by the reticuloendothelial system. notion that CXCR4 is expressed on human NSCLC cells, and that the CXCL12-CXCR4 biological axis is important in mediatthe microvascular density of primary heterotopic and orthotopic A549 tumors in SCID mice that were treated with specific neuing metastases in an organ-specific manner.
tralizing CXCL12 antibodies, as compared with preimmune se-
Depletion of CXCL12 in Vivo Does Not Alter Primary Tumor
rum. Factor VIII-related antigen was used as a marker of endo-
Size or Tumor-derived Angiogenesis
thelial cells. We found no difference in the vascular density of primary tumors from mice treated with neutralizing antiStudies have indicated that the CXCL12-CXCR4 biological axis CXCL12, as compared with preimmune serum ( Figure 11A ). may be involved in mediating angiogenesis (21, 22 ). This in turn
To further confirm that CXCL12-CXCR4 axis was not medihas led to speculation that the predominant function of this ating tumor-derived angiogenic activity, we assessed A549 tumor ligand-receptor pair in tumorigenesis results from this perceived homogenates from mice treated with either anti-CXCL12 antiangiogenic capability rather than from an ability to mediate bodies or preimmune serum in the cornea micropocket assay of metastasis. Thus, we wanted to determine whether there was neovascularization and endothelial cell chemotaxis assays. There any evidence of CXCL12-CXCR4-mediated angiogenesis in our was no difference in tumor-derived angiogenic activity between in vivo model system of heterotopic or orthotopic human NSCLC tumor growth and metastasis. On this basis, we analyzed the two treatment groups. To confirm that anti-CXCL12 antibod- Figure 10 . Neutralization of CXCL12 in animals bearing heterotopic and orthotopic A549 tumors resulted in attenuated metastases to specific organs. *p Ͻ 0.05. These findings represent a total of six organs of each type. ies were found within the tumors, we performed immunohistorevealed that although the NSCLC primary tumor and plasma chemical localization of goat IgG. Goat IgG was found to be have measurable levels of CXCL12, higher levels of CXCL12 immunolocalized within the tumors.
were observed in organs that are known to be the preferred Furthermore, there was no significant difference in size of sites of NSCLC tumor metastases (3, 4) . Moreover, several studthe heterotopic A549 tumors in mice treated with neutralizing ies have now shown that CXCR4 is abundantly expressed on anti-CXCL12 antibodies, as compared with preimmune serum cells from a number of metastatic cancers including ovarian cancer, ( Figure 11B ; p ϭ 0.64). There was no significant difference in pancreatic cancer, neuroblastoma, non-Hodgkin's lymphoma, the number of proliferating cells, as determined by immunolocaland multiple myeloma, and although these tumors arise from ization of PCNA in tumors from mice treated with neutralizing different tissues they all share the ability to migrate in response anti-CXCL12 antibodies, as compared with preimmune serum.
to CXCL12 (31, [35] [36] [37] [38] . Some of these tumors have also been The number of PCNA-positive cells per field (five fields per shown to upregulate adhesion molecules, notably members of tumor from six tumors per group) at ϫ400 was 206 Ϯ 17 and the integrin family (37, 38), which may have an important role 210 Ϯ 7 for the tumors from mice treated with neutralizing antito play in the process of metastasis. CXCL12 antibodies, as compared with preimmune serum, respecAlthough a great deal of work has contributed to our undertively (p ϭ 0.76). In addition, there was no significant difference standing of the basic pathophysiology of CXCL12-CXCR4, the in the levels of CXCL12 protein expressed by the primary tumor signaling properties of CXCR4 and CXCL12 in the proposed versus the adjacent normal skin. In a similar manner, we found regulation of organ-specific metastasis have not been well charin the orthotopic tumor model no significant difference in the acterized. Neither is it clear whether the pathways activated by magnitude of tumor burden in the lungs of animals treated with CXCL12-CXCR4 in these metastatic cancers will be similar to neutralizing anti-CXCL12 antibodies or preimmune serum (Fig- those activated in other noncancerous CXCL12-CXCR4 sysure 11C).
tems, notably T cells, neuronal cells, and hematopoietic cells (32, [39] [40] [41] . Therefore, we began our study by examining the DISCUSSION signal transduction mechanisms that may regulate the migratory process of NSCLC metastasis. Our data indicate that CXCL12 In this article we examined the interrelationship between priactivation of CXCR4 on NSCLC cell lines results in the followmary NSCLC tumor growth and metastases and the chemokine ing: (1 ) mobilization of calcium from intracellular stores, (2 ) ligand-receptor pair, CXCL12-CXCR4, in human NSCLC tuchemotaxis that is mediated by a PTX-sensitive G protein, and mor samples, human NSCLC cell lines, and human NSCLC (3 ) enhanced phosphorylation of the downstream signaling moltumors growing in SCID mice. In keeping with the results of ecules ERK-1/2. another study that demonstrated CXCR4 expression on a panel
These initial results show some differences from the other of NSCLC cell lines (34), we confirmed that A549 cells and noncancerous systems. For example, ERK-1/2 in the NSCLC Calu-1 cells express both mRNA and surface levels of this checell line A549 and in primary astrocyte cultures, but not in T mokine receptor. This is also consistent with the findings of cells, are constitutively phosphorylated (41, 42) . Furthermore, Murdoch and associates for the expression of CXCR4 on human the kinetics of phosphorylation differ, because in both T cells epithelial cells (30). Furthermore, immunohistochemical staining and astrocytes phosphorylated forms of ERK-1/2 appear within showed that Stage I and II NSCLC tumor specimens resected from patients strongly expressed CXCR4. Additional studies a few minutes of stimulation with CXCL12 and remain elevated for more than 20 minutes (41, 42) , whereas in NSCLC cells reduction in tumor size and metastatic propensity (26, 28, 45, 46) . Our data therefore suggest a dichotomy in the function for CXCL12-mediated phosphorylation of ERK-1/2 peaks abruptly at 5 minutes and then quickly returns to basal levels. Reports CXCL12 versus the other angiogenic factors, such that epithelial neutrophil activating peptide-78, interleukin-8, and vascular endoin T cells and astrocytes have shown that ligation of CXCR4 by CXCL12 activates a multitude of signaling pathways includthelial growth factor promote metastasis through their stimulatory effects on angiogenesis, whereas CXCL12 mediates metastasis ing Janus kinase-signal transducer and activator of transcription (JAK-STAT), NF-B, protein kinase C, phosphoinositide through direct effects on tumor cell migration.
In agreement with the work of Mü ller and coworkers (20), 3-kinase, and protein kinase B (32, 33, [41] [42] [43] [44] , and detailed study of these pathways in NSCLC versus noncancerous systems may our study shows that the CXCL12-CXCR4 biological axis can regulate the overall metastatic propensity of tumors without reveal important future clues to the mechanisms underlying CXCL12-CXCR4-mediated NSCLC tumor metastasis.
changing their proliferative capacity, and also provides the first in vivo evidence to suggest that this chemokine ligand-receptor The expression of CXCR4 on NSCLC tumor cells in vitro and in vivo in primary tumors is heterogeneous. It is possible, pair can mediate the metastasis of NSCLC tumor cells. In our murine paradigms of heterotopic and orthotopic tumor growth, therefore, that the expression of this receptor is sensitive to the local milieu in which the tumor cell resides. In the confined A549 tumor cells found at the sites of organ metastases were almost exclusively CD49b ϩ CXCR4 ϩ double positive. By conenvironment of a tumor the concentration of appropriate chemokines, cytokines, and other potential factors are likely to be trast, in the primary tumor itself, only 65% of A549 cells were found to be CD49b ϩ CXCR4 ϩ double positive, leaving 35% as elevated, and thus CXCR4 expression can be maintained at high levels. Thus, it will be important to characterize which factors CD49b
These results suggest that in spite of the phenotypic heterogeneity of the A549 cells within the primary tufound within the tumor microenvironment have the ability to modulate CXCR4 expression. Once we have a greater appreciamor, only those A549 cells that are CD49b ϩ CXCR4 ϩ double positive were destined to metastasize to distant organs. tion of the mechanisms that govern the expression of CXCR4 on NSCLC tumor cells we will improve our understanding of Data from SCID mice heterotopically and orthotopically xenoengrafted with A549 cells revealed that NSCLC tumor mehow CXCR4, itself, regulates NSCLC tumor metastasis.
Mü ller and colleagues (20) have provided direct evidence to tastases to specific organs were significantly reduced, although not completely abrogated, in the presence of neutralizing antisupport the notion that the CXCL12-CXCR4 biological axis can actually mediate human carcinoma metastasis in vivo. Their CXCL12 antibodies. There are at least two possibilities to account for the continued expression of NSCLC metastases in article provided evidence that the CXCL12-CXCR4 biological axis is involved in the metastatic propensity of breast cancer to mice treated with neutralizing anti-CXCL12 antibodies. First, the anti-CXCL12 antibody administration was incomplete in specific organs (20) . This group has demonstrated that CXCR4 is highly expressed on human breast cancer cells, malignant blocking all CXCL12 to its cognate CXCR4 receptor, and second, it is possible that other mechanisms, in addition to the breast tumors, and metastases. Furthermore, CXCL12 mRNA exhibited peak levels of expression in organs that are the pre-CXCL12-CXCR4 biological axis, could be involved in NSCLC tumor metastasis. ferred sites of breast cancer metastasis. Signaling through CXCR4 in breast cancer cells mediated actin polymerization and CXCR4-mediated NSCLC metastasis to distant organs requires a CXCL12 chemotactic gradient. On measuring levels of pseudopodia formation and, subsequently, induced chemotactic and invasive responses at the local level. Finally, in vivo neutral-CXCL12 protein in a variety of organs, we found that the majority of CXCL12 protein was elaborated in organs correlated with ization of CXCR4 with specific anti-CXCR4 antibodies resulted in significant inhibition of metastasis of breast cancer cells to organ-specific metastases of NSCLC. On the other hand, little or no CXCL12 protein was found in the heart or kidneys, which regional lymph nodes and the lung (20).
Our results complement this work, and address two potential contained few, if any, metastases. Furthermore, when we compared CXCL12 levels from these organs to the primary tumor criticisms of Mü ller's original findings. First, by using antibodies targeted to CXCR4, it could be argued that breast cancer metasand plasma levels, we observed that CXCL12 expression in adrenal glands, lung, liver, and bone marrow, but not in kidneys and tasis was reduced because the cells were being eliminated by the reticuloendothelial system, rather than because their migratory heart, was significantly higher than in either primary tumor or plasma. Under these conditions, once the tumor cell has escaped ability had been abrogated though loss of CXCR4 function. Our study obviates that criticism, because the antibodies we used the primary tumor, it would be possible for a CXCL12 chemotactic gradient to develop that would facilitate metastasis of A549 are directed toward CXCL12 rather than to CXCR4-bearing NSCLC cells. Second, studies have suggested a possible role of CD49b ϩ CXCR4 ϩ double-positive cells from the primary tumor to specific organs. In addition, it should be borne in mind that the CXCL12-CXCR4 biological axis in mediating tumorigenesis via the promotion of angiogenesis, rather than the regulation of the levels of CXCL12 observed in these organs represent an average concentration, and it is entirely possible that within the metastasis (21, 22). However, our studies revealed that tumorderived angiogenic activity remained unchanged in primary tuorgan microenvironment the local concentration of CXCL12 could be substantially higher, creating an even greater chemotacmors of animals depleted of CXCL12, indicating that the function of this chemokine may not be as important in promoting tic gradient to further attract metastatic A549 CD49b ϩ CXCR4 ϩ double-positive cells. angiogenesis in the local tumor microenvironment. One possible explanation for this is that there are many more CXCR4-bearing Our work, together with that of others, correlates well with an extensive body of research showing that chemokines play a tumor cells than CXCR4 ϩ endothelial cells in the local microenvironment of the tumor, and the tumor cells are able to outpivotal role in leukocyte trafficking and homeostasis (8, 12, (47) (48) (49) (50) (51) . The nature of this regulation has shown that chemokines compete the endothelial cells for the available CXCL12. In contrast, known angiogenic factors (i.e., epithelial neutrophil not only mediate tissue-specific homing of leukocytes, they also dictate microenvironmental separation of lymphocyte subsets activating peptide-78, interleukin-8, and vascular endothelial growth factor) are found to be elevated in human NSCLC, as within primary and secondary lymphoid organs (48, 52) . In this regard CXCL12 is known to be involved in directing progenitor compared with normal lung tissue (26, 28, 45, 46) . Furthermore, the addition of neutralizing antibodies to these angiogenic factors cells into the appropriate maturation sites in the bone marrow (53) . In addition, CXCL12 may support the colonization of the resulted in a net reduction of angiogenesis, and a consequent and derailed cerebellar neuron migration in CXCR4-and SDF-1-bone marrow by hematopoietic precursors during embryogenedeficient mice. Proc Natl Acad Sci USA 1998;95:9448-9453. sis (54) . Clearly the bone marrow is a sensitive site for CXCL12 
